Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsNoel Turner, MD, MHS, FAAD
Clinical InstructorDownloadHi-Res Photo
About
Copy Link
Departments & Organizations
- Yale New Haven Health System
Education & Training
- MHS
- Yale School of Medicine (2019)
- MD
- Yale School of Medicine (2019)
- BA
- Johns Hopkins University, Neuroscience
Research
Copy Link
Overview
Medical Research Interests
Dermatology; Melanoma
ORCID
0000-0001-7537-6449
Research at a Glance
Yale Co-Authors
Frequent collaborators of Noel Turner's published research.
Publications Timeline
A big-picture view of Noel Turner's research output by year.
Research Interests
Research topics Noel Turner is interested in exploring.
Marcus Bosenberg, MD, PhD
William Damsky, MD, PhD
Curtis Jamison Perry, MD, PhD
Harriet Kluger, MD
Jonathan Leventhal, MD
Anjela Galan, MD
10Publications
316Citations
Melanoma
Publications
2024
Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review
Turner N, Ko C, McNiff J, Galan A. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review. American Journal Of Dermatopathology 2024, 46: 21-30. PMID: 37982498, DOI: 10.1097/dad.0000000000002584.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsConventional malignant melanomaMalignant melanomaPRAME immunohistochemistryBorderline lesionsNonmelanocytic lesionsDysplastic neviAmerican Joint CommitteePathological tumor stageMalignant melanocytic proliferationsBanal melanocytic nevusUlceration statusInstitution experienceBreslow depthMean ageTumor stageClinicopathologic correlationConsecutive casesMale genderAtypical fibroxanthomaSevere atypiaJoint CommitteeLarge seriesAmbiguous melanocytic lesionsMelanocytic proliferationMalignant counterparts
2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, PMCID: PMC12645833, DOI: 10.1158/2326-6066.cir-22-0699.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPD-1 resistanceDendritic cellsTumor regressionAnti-PD-1 resistanceActivates Dendritic CellsCytokine secretion profilingSystemic cytokine profileTriple therapy combinationInnate immune activationAdaptive immune responsesComplete tumor regressionMajority of miceSignificant clinical challengeMouse melanoma modelT cell activationAgonistic CD40Checkpoint inhibitorsDC subsetsTriple therapyCytokine profileImmune activationCombinatorial immunotherapyTherapy combinationsT cellsClinical challenge
2022
Facial hyperpigmentation and crusted papules on the hands.
Leasure AC, Turner N, Lim I. Facial hyperpigmentation and crusted papules on the hands. JAAD Case Reports 2022, 20: 23-25. PMID: 35036499, PMCID: PMC8753054, DOI: 10.1016/j.jdcr.2021.09.043.Peer-Reviewed Original Research
2021
Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination
Tomayko MM, Damsky W, Fathy R, McMahon DE, Turner N, Valentin MN, Rallis T, Aivaz O, Fox LP, Freeman EE. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. The Journal Of Allergy And Clinical Immunology 2021, 148: 750-751. PMID: 34275656, PMCID: PMC8280592, DOI: 10.1016/j.jaci.2021.06.026.Peer-Reviewed Original ResearchCitationsAltmetric
2020
Recurrent cutaneous Exophiala phaeohyphomycosis in an immunosuppressed patient.
Turner N, Kibbi N, Panse G, Imaeda S. Recurrent cutaneous Exophiala phaeohyphomycosis in an immunosuppressed patient. Cutis 2020, 106: e7-e8. PMID: 33465199, DOI: 10.12788/cutis.0120.Peer-Reviewed Case Reports and Technical NotesCitations
2019
LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma
Krykbaeva I, Damsky W, Turner N, Perry C, Kluger H, Bosenberg M. LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma. Journal Of Investigative Dermatology 2019, 139: b19. DOI: 10.1016/j.jid.2019.06.089.Peer-Reviewed Original ResearchB cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkage
2018
Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinoma
Turner N, Leventhal J. Atezolizumab‐associated vitiligo‐like leukoderma in a patient with transitional cell carcinoma. International Journal Of Dermatology 2018, 57: e90-e92. PMID: 30091457, DOI: 10.1111/ijd.14191.Peer-Reviewed Original ResearchCitationsGenetics of metastasis: melanoma and other cancers
Turner N, Ware O, Bosenberg M. Genetics of metastasis: melanoma and other cancers. Clinical & Experimental Metastasis 2018, 35: 379-391. PMID: 29722002, DOI: 10.1007/s10585-018-9893-y.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts1245 PD-1 blockade impedes tumor growth in the immunogenic YUMMER1.7 mouse melanoma model
Turner N, Damsky W, Wang J, Meeth K, Blenman K, Bosenberg M. 1245 PD-1 blockade impedes tumor growth in the immunogenic YUMMER1.7 mouse melanoma model. Journal Of Investigative Dermatology 2018, 138: s211. DOI: 10.1016/j.jid.2018.03.1260.Peer-Reviewed Original Research